Haleon PLC Sponsored ADR $HLN Shares Purchased by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC increased its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 52.2% during the second quarter, HoldingsChannel.com reports. The fund owned 23,429 shares of the company’s stock after buying an additional 8,035 shares during the period. Transcend Capital Advisors LLC’s holdings in Haleon were worth $243,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Envestnet Asset Management Inc. boosted its position in Haleon by 6.5% during the second quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock worth $81,479,000 after acquiring an additional 476,823 shares during the last quarter. Resonant Capital Advisors LLC boosted its position in Haleon by 6.4% during the second quarter. Resonant Capital Advisors LLC now owns 29,432 shares of the company’s stock worth $305,000 after acquiring an additional 1,761 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in Haleon during the second quarter worth about $671,000. Pittenger & Anderson Inc. acquired a new position in Haleon during the second quarter worth about $36,000. Finally, Drive Wealth Management LLC boosted its position in Haleon by 438.3% during the second quarter. Drive Wealth Management LLC now owns 74,517 shares of the company’s stock worth $773,000 after acquiring an additional 60,675 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Barclays lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Stock Up 1.5%

Shares of NYSE:HLN opened at $9.19 on Friday. The business has a 50-day moving average price of $9.33 and a 200 day moving average price of $9.96. The company has a market capitalization of $40.90 billion, a price-to-earnings ratio of 23.55, a PEG ratio of 2.64 and a beta of 0.20. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48.

Haleon Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were paid a $0.0555 dividend. This is a positive change from Haleon’s previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. This represents a dividend yield of 190.0%. Haleon’s payout ratio is presently 28.21%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.